NCT01260350 - Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

December 31, 2013

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

SOF

Sofosbuvir (SOF) tablets administered orally once daily

DRUG

RBV

Ribavirin (RBV) capsules administered orally in a divided daily dose

DRUG

PEG

Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly

DRUG

LDV

Ledipasvir (LDV) tablets administered orally once daily

DRUG

GS-9669

GS-9669 tablets administered orally once daily

DRUG

LDV/SOF

LDV/SOF fixed-dose combination (FDC) tablet administered once daily

Trial Locations (2)

Auckland Clinical Studies Ltd., Auckland

Christchurch Clinical Studies Trust, Christchurch